Insider Selling: Applied Therapeutics, Inc. (NASDAQ:APLT) Insider Sells 22,950 Shares of Stock

On February 6th, 2023, Leslie D. Funtleyder, an insider at Applied Therapeutics, Inc. (NASDAQ: APLT), sold 22,950 shares of the company's stock. The shares were sold at an average price of $0.61 per share, resulting in a total transaction value of $13,999.50. After this sale, Funtleyder now holds 404,961 shares in the company, which are estimated to be worth around $247,026.21. This sale represents a decrease of 5.36% in their total ownership of the stock. The details of this transaction have been filed and are available for public viewing through the SEC.

Stock Performance of Applied Therapeutics

Applied Therapeutics Stock Status

During midday trading on the following Friday, shares of Applied Therapeutics remained stable at $0.61. A total of 1,845,842 shares traded hands, while the average volume is typically around 5,416,228 shares. The firm's fifty-day moving average price stands at $0.90, and its 200-day moving average price is $5.14. Currently, Applied Therapeutics has a market capitalization of $70.99 million, a price-to-earnings ratio of -0.38, and a beta value of 1.88. Over the past year, the stock has fluctuated between a low of $0.54 and a high of $10.62.

Latest Analyst Assessments

A number of research analysts have recently provided updates on APLT shares. UBS Group maintained a "neutral" rating but lowered its target price to $2.00 from $13.00. Robert W. Baird also reduced their target from $14.00 to $5.00 while rating the stock as "outperform." Citigroup similarly cut its price objective from $13.00 to $8.00 with a "buy" rating. William Blair decreased its rating for Applied Therapeutics from "outperform" to "market perform." Lastly, Royal Bank of Canada set their new price target at $1.50, down from $4.00, assigning a "sector perform" rating. In total, three analysts currently give the stock a hold rating, while four suggest a buy rating. According to MarketBeat.com, it has a consensus rating of "Moderate Buy" alongside an average target price of $6.10.

Institutional Moves in Applied Therapeutics

Institutional Trading Trends

Recently, several institutional investors have adjusted their stakes in Applied Therapeutics. SG Americas Securities LLC enhanced its position by 169.0% in the fourth quarter, acquiring a total of 40,747 shares valued at approximately $35,000 after buying an additional 25,601 shares. Private Advisor Group LLC also entered a new position worth $35,000 during the same time. Other investments include Algert Global LLC, which purchased a position valued at around $110,000, and Y Intercept Hong Kong Ltd, which acquired shares worth $149,000. Lastly, Intech Investment Management LLC bought shares valued at roughly $162,000. Overall, institutional investors hold 98.31% of the company's stock.

About Applied Therapeutics

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates targeting unmet medical needs within the United States. The company's primary pipeline product is AT-007, also known as govorestat, which has successfully completed phase 3 trials for treating galactosemia. This candidate is also involved in pediatric studies focusing on the same condition.

Note: This article is informational and does not constitute financial advice. Always conduct your own research or consult with a professional before making investment decisions.

Insider, Selling, Shares